A chart review of 500 drug uses during a three-month period in a family practice clinic showed that 46 (9.2%) were for indications not included in the Food and Drug Administration-approved labeling. Dipyridamole was the drug most frequently and consistently prescribed for unlabeled indications. On no occasion did the chart show that patients were informed that a drug was being prescribed for an unlabeled indication. Unlabeled indications most frequently encountered in the chart review were also frequently mistaken by family practice residents and faculty responding to a questionnaire as being included in FDA-approved labeling. The indications as listed in the manufacturers' literature (eg, package insert, Physician's Desk Reference) often do not reflect how drugs are used in clinical practice.
(JAMA 243:1543-1546, 1980)
Erickson SH, Bergman JJ, Schneeweiss R, Cherkin DC. The Use of Drugs for Unlabeled Indications. JAMA. 1980;243(15):1543–1546. doi:10.1001/jama.1980.03300410031020
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: